Martin Vogelbaum - 04 Jun 2024 Form 4 Insider Report for Cara Therapeutics, Inc. (TVRD)

Reporting relationship: Director
Issuer ticker: TVRD
Reported as of: 04 Jun 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 06 Jun 2024, 16:22:30 UTC
Prior SEC filing: 05 Jun 2023
Source filing: View source filing
Reporting owner signature: /s/ Darren DeStefano, Attorney-in-Fact

Key filing fact

Martin Vogelbaum filed Form 4 for Cara Therapeutics, Inc. (TVRD) on 06 Jun 2024.

Key facts

This page summarizes Martin Vogelbaum's Form 4 filing for Cara Therapeutics, Inc. (TVRD).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 06 Jun 2024, 16:22.

Change

Previous filing in this sequence was filed on 05 Jun 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CARA transaction

Common Stock

Award

Transaction value: $0
Shares: +301,295
Change %: +275%
Price: $0.000000
Shares after: 411,007
Date: 04 Jun 2024
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CARA transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +390,000
Change %
Price: $0.000000
Shares after: 390,000
Date: 04 Jun 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 390,000
Exercise price: $0.6640
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents the number of shares underlying restricted stock units ("RSUs") granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest on the earlier of (i) June 4, 2025 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date.

Footnote F2

This option was granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on the earlier of (i) June 4, 2025 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date.